What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetes (5 trials), Type 2 Diabetes (2 trials), T2D
- Main trialPhase 3
- “This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.”In the company’s words, NCT06767748 on ClinicalTrials.gov
- Other names
- Degludec · Icodec
Other drugs for Diabetes
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 7 Feb 2026 | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | |
| Phase 3Active, not recruiting | 19 Mar 2026 | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin | |
| Phase 3Active, not recruiting | 1 Aug 2026 | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) | |
| Phase 3Recruiting | 10 Nov 2026 | A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | |
| Phase 1Not yet recruiting | 30 Sep 2025 | A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects | |
| Phase 1Recruiting | 1 Apr 2026 | Comparison Study of Insulin GZR4 With Insulin Degludec | |
| Phase 1Active, not recruiting | 14 Jul 2026 | Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment | |
| Phase 1Not yet recruiting | 29 Jul 2026 | Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants | |
| Phase 2Completed | 13 Jul 2024 | A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus | |
| Phase 1Completed | 24 Mar 2023 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4 | |
| Phase 1Completed | 1 Nov 2023 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes | |
| Phase 1Completed | 20 Aug 2024 | Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment | |
| Phase 1Unknown | 31 Aug 2024 | A Study of GZR4 Injection at Different Injection Sites |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026